VIDEO: Allogeneic transplant shows potential in high-risk multiple myeloma
Allogeneic hematopoietic cell transplantation showed potential in patients with high-risk multiple myeloma, according to findings presented at the ASCO Annual Meeting.
Allogeneic hematopoietic cell transplantation has always been “a very difficult topic” in multiple myeloma, but the approach may be “more feasible” for younger patients with very aggressive disease in certain situations, Cristina Gasparetto, MD, director of the multiple myeloma program at Duke University, told Healio in a video interview.
“We were pleasantly surprised by the favorable outcome in this difficult population of patients,” Gasparetto said. “The transplant related mortality always has been a barrier to proceed with allogenic transplant in this population of patients, but the transplant-related mortality was actually very low – around 5%.”